April 29, 2020 / 8:34 PM / a month ago

BRIEF-Marker Therapeutics Receives FDA Orphan Drug Designation For Its Multi-Antigen Targeted T Cell Therapy For Acute Myeloid Leukemia

April 29 (Reuters) - Marker Therapeutics Inc:

* MARKER THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ITS MULTI-ANTIGEN TARGETED T CELL THERAPY FOR ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below